Warmuth, M. (2009): Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 04.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
Rituximab, an anti-CD20 monoclonal antibody, has been approved for the treatment of various non-Hodgkin lymphomas for years. Recently two phase III trials assessed the benefit of adding rituximab to common chemotherapy regimens for the first- and second-line treatment of chronic lymphocytic leukaemia (CLL). Although both trials showed a significantly increased complete remission rate and progression-free survival in the intervention compared to the control group, there was no difference in overall survival between the two groups. Because rituximab is an add-on to existing treatment regimens and CLL is on the rise in Austria due to an ageing population, the financial impact of adding rituximab will be substantial.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Keywords:||Rituximab, Rituxan, MabThera, monoclonal antibody, CLL, NHL, Oncology|
|Subjects:||QZ Pathology > QZ 200-380 Neoplasms.Cysts|
WH Hemic and lymphatic systems
|Series Name:||DSD: Horizon Scanning in Oncology 04|
|Deposited on:||02 Nov 2009 16:20|
|Last Modified:||02 Nov 2009 16:20|
Repository Staff Only: item control page